BioCentury | Jun 2, 2017
Clinical News

CASI completes enrollment in Phase II of ENMD-2076 for TNBC

...CASI Pharmaceuticals Inc. (NASDAQ:CASI) completed enrollment of 41 patients in a Phase II trial of ENMD-2076...
...mg oral ENMD-2076 daily in 28-day cycles. The primary endpoint is clinical benefit rate (CBR). ENMD-2076...
...kinase A (AURKA; Aurora-A) and multiple tyrosine kinases. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: ENMD-2076...
BioCentury | Jun 2, 2017
Clinical News

CASI reports Phase II data for ENMD-2076 in clear cell ovarian cancer

...clear cell ovarian cancer in a Phase II trial showing that once-daily 275 mg oral ENMD-2076...
...patients (n=17), median PFS was 3.6 months and the estimated 6-month PFS rate was 12%. ENMD-2076...
...response, biomarkers and safety. The trial was conducted by the Princess Margaret Phase 2 Consortium. ENMD-2076...
BioCentury | Oct 27, 2016
Translation in Brief

Blueprint for fusion

...one other company is developing a therapy for fibrolamellar carcinoma: CASI Pharmaceuticals Inc. (NASDAQ:CASI) has ENMD-2076...
BioCentury | Sep 5, 2016
Clinical News

ENMD-2076: Interim Phase II data

...1 of a 2-stage, open-label, U.S. Phase II trial showed that once-daily 250 mg oral ENMD-2076...
...stage 2 and enroll an additional 13 patients. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: ENMD-2076...
BioCentury | Nov 23, 2015
Clinical News

ENMD-2076: Phase II started

...CASI began an open-label, U.S. Phase II trial to evaluate 250 mg oral ENMD-2076 once daily...
...daily in 28-day cycles in about 29 patients. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: ENMD-2076...
BioCentury | Aug 18, 2014
Clinical News

ENMD-2076: Phase II data

...metastatic STS in the open-label, single-arm, Canadian Phase II Study 2076-STS-001 showing that once-daily oral ENMD-2076...
...and diarrhea. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ENMD-2076...
...multiple myeloma (MM) and acute myelogenous leukemia (AML). CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: ENMD-2076...
BioCentury | Jul 28, 2014
Clinical News

ENMD-2076 regulatory update

...CASI (formerly EntreMed Inc. ) said FDA granted Orphan Drug designation to ENMD-2076 to treat hepatocellular...
...multiple myeloma (MM) and acute myelogenous leukemia (AML). CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: ENMD-2076...
BioCentury | Aug 8, 2013
Distillery Therapeutics

Indication: Cancer

...treat T cell lymphoma and Phase II testing or earlier for other cancers. EntreMed Inc.'s ENMD-2076...
BioCentury | Aug 5, 2013
Clinical News

ENMD-2076: Phase I started

...EntreMed began a single-blind, dose-escalation, crossover, U.S. Phase I trial to evaluate 2 doses of ENMD-2076...
...FDA's requirement on the formulated product of ENMD-2076 that can be used for pivotal trials. ENMD-2076...
...cancer, multiple myeloma (MM) and acute myelogenous leukemia (AML). EntreMed Inc. (NASDAQ:ENMD), Rockville, Md. Product: ENMD-2076...
BioCentury | Mar 11, 2013
Regulation

Dissecting Kadcyla

...Co. (NYSE:LLY) Icrucumab (IMC-18F1) Human IgG1 mAb against VEGFR-1 (FLT1) Ph II EntreMed Inc. (NASDAQ:ENMD) ENMD-2076...
Items per page:
1 - 10 of 40